semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Hypertension Premature Birth Participant is willing and able to give informed consent for participation in the study Male or Female, from 18 to 35 years old Verified birth history: preterm birth (<37 weeks) or full-term birth (>37 weeks) Ability to access and use computer/internet Willing to complete duration of intervention, follow-up and attend study visits at the John Radcliffe Hospital (participants may still withdraw at any time without providing an explanation or rationale) hour awake ABP greater than 115/75 mmHg Able (in the investigator's opinion) and willing to comply with all study requirements  Clinic blood pressure greater than 159mmHg systolic and/or 99mmHg diastolic at initial screening Pregnancy hour awake ABP greater than 150mmHg systolic and/or 95mmHg diastolic Clinic blood pressure greater than 140mmHg systolic and/or 90 mmHg diastolic plus evidence of end organ damage secondary to hypertension Simultaneous participation in another human or clinical randomized trial (if there is any possibility of compromising health, safety, or well-being, or any possible compromise of study data) Unable to walk briskly on the flat for 15 minutes Those currently maintaining levels of cardiovascular fitness and activity at or above the levels required for the intervention arm Unable to attend the regular supervised exercise sessions Use of beta-blockers such as atenolol or equivalent BMI >35 kg/m2
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Anemia The patient would otherwise receive RBC transfusion for treatment of severe anemia but cannot (hemolytic/allosensitized or no compatible blood) or will not (religious/personal objection) receive RBCs 2. Hemoglobin ≤ 5 g/dL, or hemoglobin ≤ 7 g/dL following a decline of ≥ 5 g/dL over less than 7 days 3. Age ≥ 18 years 4. Receiving or willing to receive supplemental iron therapy (unless contraindicated) 5. Receiving or willing to receive erythropoiesis-stimulating agent (EPO) therapy 6. Patient or legally authorized representative provided consent to participate 7. Investigator determination that the patient is an appropriate candidate for study enrollment  Hemoglobin ≤ 2 g/dL 2. Presence of severe trauma (e.g., Injury Severity Score (ISS)/New Injury Severity Score (NISS) Score ≥ 25) 3. Unable to provide sufficient blood sample volume for screening assessments; or 4. Pregnant; or 5. Investigator determination that the patient is not an appropriate candidate for study enrollment
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Pancreatic Cancer patients undergoing all different kinds of pancreatic surgery in elective setting for cancer with a pancreatic anastomosis performed  age < 18 years pregnant women patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cartilage Damage Degenerative Osteoarthritis Patients whose lesion (single joint) should be in the range of 2 cm^2-8 cm^2 Patients with pain in affected joint of 60 mm mm VAS (visual analogue scale) Patients with articular swelling, tenderness and active range of motion of Grade 2 or below Patients with knee joint cartilage defect or injury of ICRS (International Cartilage Repair Society) Grade 4 confirmed by arthroscopy (At screening, patients diagnosed as such with an MRI may be included) Patients who needs invasive interventions of arthroplasty due to no response from existing pain medication Patients voluntarily agreed to participate in the study and signed informed consent  Patients with autoimmune diseases or medical history Patients with infections requiring injection of antibiotics Patients with severe internal diseases Patients who are currently pregnant or lactation Patients who had participated in any other clinical trials within the past four weeks Patients who had been administered with immunosuppressants within the past four weeks Patients whom the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Immunology of Septic Shock septic shock is defined by an identifiable site of infection, persisting hypotension despite fluid resuscitation requiring vasopressor therapy, and evidence of a systemic inflammatory response  age < 18 immunosuppressive disease (HIV, cancer, primary immune deficiency) immunosuppressive treatment or corticoid treatment (dosage > 10mg/day or cumulative dose >700 mg equivalent prednisolone) aplasia as defined by number of circulating neutrophils < 500 cells / mm3 extracorporeal circulation during the month prior ICU admission
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Meningococcal Disease Individual is willing and able to give written informed consent for participation Individual was originally enrolled in the randomised parallel group study of quadrivalent meningococcal vaccination  Known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time) Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Q Fever Auto-Immunity Patients with a current or former Q fever diagnosis Patient > or = 18 years old Patient who does not declined to have his medical records reviewed for research Patient with health insurance  Minor patient (<18 years ) Adult patient under guardianship  Patient deprived of liberty or judgment Patient refusing to sign the informed consent form
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Autoimmune Hemolytic Anemia Patients with a diagnosis of warm AIHA defined by Hemoglobin <11 g/dl Low haptoglobin level Positive direct antiglobulin test (IgG or IgG + complement) Reticulocyte count >120 G/L Patients naive to treatment for hemolytic anemia or a in relapse Older than 18 years Able to understand written and spoken French Persons who have provided written consent Control population  Patients without national health insurance Pregnancy or breast-feeding women Adults under guardianship Patients with cancer or malignant hemopathy Patients with an on-going infection Patients treated with corticoids or immunosuppressants
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Blood Coagulation Tests patient treated with oral anticoagulant at curative dose and requiring a requiring a venous blood sample for his management  opposition to the patient to participate to the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Purpura, Thrombotic Thrombocytopenic Age 18 years or above Diagnosed with acquired TTP with levels of ≤ 10 % in clinical remission and with measurable or previously confirmed antibodies  Prior malignancy within 5 years Test positive for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV) Ongoing infectious disease including P-CRP >10 Test positive for IgE antibodies against IdeS Secondary cause of TTP Rituximab treatment or other antibody-based therapy within 7 days prior to IdeS dosing Treatment with investigational medicinal product within the last 12 weeks proceeding screening Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure > NYHA (New York Heart Association) grade 3, unstable coronary disease or oxygen dependent COPD History of any other clinically significant disease or disorder which may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study Hypogammaglobulinemia defined as any values of P-total IgG less than 3 g/L
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.667,  Heart Arrest Birth Asphyxia Bradycardia Infants (term or preterm infants >28 weeks' gestation) requiring CC in the delivery room will be eligible for the trial  Infants will be excluded if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation (e.g. congenital diaphragmatic hernia), or congenital heart disease requiring intervention in the neonatal period. Infants would be also excluded if their parents refused to give consent to this study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thrombocytopenia hospitalized patients with suspicion of thrombocytopenia drug consent signed  Thrombocytopenia plants such as secondary to the following molecules: antineoplastic (except oxaliplatin which gives TIM), immunosuppressants Induced thrombocytopenia heparin and IIb / IIIa glycoproteins (abciximab, tirofiban, epifibatide) Presence of anti platelet antibodies allogeneic or autoimmune which are part of the MAIPA test Patient exposed to at least one suspect molecule does not exist in water-soluble form or drug to which the metabolite is suspected Patients transfused (plasma, platelets) for less than a month Patients with an other bloodline
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Critical Illness Respiratory Disease Hypoxemia(SpO2/FiO2< 315 (15))(indication for chest physiotherapy)(cf. annexe 1) Medical prescription for chest physiotherapy First session of chest physiotherapy Chest X-ray<12h available Physiotherapist/operator qualified in LUS available Patient's consent  Presence of a contra-indication for chest physiotherapy Absence of hypoxemia Absence of a prescription for chest physiotherapy Absence of a chest X-ray < 12h from the time of physiotherapy assessment Physiotherapist/operator qualified in LUS not available Lung and diaphragm US not possible (surgical emphysema, dressing, scarring, drains etc.) Refusal of the patient or a relative to participate in the study Patients to be discharged on the day of the study Patients in palliative care Withdrawal/limitations of medical care with impending death
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hemolytic Uremic Syndrome Patients with a clinical diagnosis of typical or atypical HUS in acute phase  Patient with positive serological screening test for infection with the HIV Patients with a history of cancer Patients who have undergone organ transplantation or bone marrow Patient with a vivid picture of autoimmune thrombotic thrombocytopenic purpura
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bacteremia Patient is in the hospital ward and not in the intensive care units at time the blood culture result reported as positive AND 2. Patient has a positive blood culture with pathogenic bacteria  Patient already enrolled in either of the trials 2. Patient is admitted in the ICU at the time of enrollment 3. Patient has severe immune system compromise, as defined by: absolute neutrophil count <0.5x109/L; or is receiving immunosuppressive treatment for solid organ or bone marrow or stem cell transplant 4. Patient has a prosthetic heart valve or synthetic endovascular graft 5. Patient has documented or suspicion of syndrome with well-defined requirement for prolonged treatment: i) infective endocarditis; ii) osteomyelitis/septic arthritis; iii) undrainable/undrained abscess; iv) unremovable/unremoved prosthetic-associated infection 6. Patient has a single positive blood culture with a common contaminant organism according to Clinical Laboratory & Standards Institute (CLSI) Guidelines: coagulase negative staphylococci; or Bacillus spp.; or Corynebacterium spp.; or propionobacterium spp.; or Aerococcus spp.; or Micrococcus spp. 7. Patient has a positive blood culture with Staphylococcus aureus. 8. Patient has a positive blood culture with Candida spp. or other fungal species